Full Steam Ahead For Exelixis' Phase III Glioblastoma Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The study of about 400 patients will not be open to patients who have received Roche/Genentech's Avastin, which was approved in 2009 for recurrent disease.